Knight Therapeutics Company Profile (CVE:GUD)

Analyst Ratings

Consensus Ratings for Knight Therapeutics (CVE:GUD) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Knight Therapeutics (CVE:GUD)
Show:
DateFirmActionRatingPrice TargetActions
3/6/2015MackieInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/2/2015LB SecuritiesReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/28/2014NBFInitiated CoverageOutperformC$6.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/23/2014 forward)

Earnings

Earnings History for Knight Therapeutics (CVE:GUD)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Knight Therapeutics (CVE:GUD)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Knight Therapeutics (CVE:GUD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Knight Therapeutics (CVE:GUD)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Knight Therapeutics (CVE:GUD)
DateHeadline
07/22/16 07:17 AM3D Signatures Inc. and Plicit Capital Corp. Execute Definitive Licencing and Distribution Agreements With Knight Therapeutics Inc.
07/15/16 03:25 PMKnight Acquires Minor Stake in Pediapharm
05/26/16 11:31 AMKNIGHT THERAPEUTICS INC - ... 5,000,000 (the "Financing") and entered into an advisory services agreement (the "Agreement") with Knight Therapeutics Inc. ("Knight") (TSX: GUD). Knight has committed to the Financing with an equity investment of not less than $1,000,000. The ...
05/26/16 11:16 AM3D Signatures Inc. and Plicit Capital Corp. Increase Minimum Financing and Receive Lead Order From and Enter Into Advisory Agreement With Knight Therapeutics Inc. -
05/10/16 05:00 AMKnight Reports First Quarter 2016 Results -
04/25/16 07:00 AMKnight Blooms at Healthcare Investor Conference in Toronto -
04/25/16 07:00 AMKnight Receives NOD from Health Canada for ATryn(R) -
04/25/16 07:00 AMKnight Finds EMPAthetic Partner for Neuragen(R) in the Middle East -
03/24/16 06:07 AMQ4 2015 KNIGHT THERAPEUTICS Inc Earnings Release - Time Not Supplied -
03/24/16 05:00 AMKnight Reports Fourth Quarter and Year-Ended December 31, 2015 Results -
03/23/16 07:00 AMKnight Receives Dividend From Medison -
03/22/16 07:03 AMKnight Partner Profounda Inc. Launches Impavido in U.S. -
03/22/16 06:59 AMProfounda, Inc. launches Impavido® (miltefosine), the first and only oral Rx treatment for visceral, mucosal and cutaneous leishmaniasis, in the United States -
03/15/16 07:00 AMKnight Obtains Impavido Worldwide Rights -
01/16/16 01:29 PMKnight Therapeutics Inc. (GUD.TO) - Knight Therapeutics Inc., a specialty pharmaceutical company, engages in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products in Canada and internationally. The company offers Impavido for the treatment of ...
12/22/15 07:00 AMKnight Loan to Extenway Impaired -
12/18/15 08:42 AMKnight Therapeutics, Inc. Earnings Analysis: Q3, 2015 By the Numbers -
12/11/15 07:00 AMKnight Takes Right Angle With 60 Degrees Pharmaceuticals LLC -
12/09/15 08:21 AMKnight Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : December 9, 2015 -
11/25/15 07:00 AMCRH Makes GUD on Knight Secured Loan -
11/17/15 07:00 AMKnight to Present at the TD Securities Technology & Healthcare Conference in Toronto -
11/16/15 07:00 AMKnight Partner FOCUSed on Growth -
11/16/15 07:00 AMKnight Supports Operation Antibe -
11/11/15 08:37 AMKnight Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : November 11, 2015 -
11/11/15 05:00 AMKnight Reports Third Quarter Financial 2015 Results -
11/02/15 07:00 AMThe Knight Medison Relationship Already Paying Dividends -
10/28/15 12:55 PMKnight Therapeutics, Inc. – Value Analysis (TORONTO:GUD) : October 28, 2015 -
10/15/15 09:11 AMKnight Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : October 15, 2015 -
09/28/15 07:00 AMKnight Profounda U.S. Partner for Impavido -
09/15/15 09:56 AMKnight Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : September 15, 2015 -

Social

About Knight Therapeutics

Knight Therapeutics Inc. (Knight) is a specialty pharmaceutical company. The Company is focused on developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products. The Company's product pipeline consists of the product Impavido (miltefosine), an alkyllysophospholipid analogue drug with in vitro activity against the promastigote and amastigote stages of Leishmania species. Impavido is an oral agent indicated for the treatment of visceral and cutaneous leishmaniasis and was included in the World Health Organization (WHO) essential medicines list as an anti-leishmaniasis medicine.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: CVE
  • Symbol: GUD
  • CUSIP:
Key Metrics:
  • Previous Close: $8.47
  • 50 Day Moving Average: $8.32
  • 200 Day Moving Average: $7.74
  • P/E Ratio: 41.32
  • P/E Growth: -5943.00
  • Market Cap: $876.46M
  • Current Year EPS Consensus Estimate: $0.14 EPS
  • Next Year EPS Consensus Estimate: $N/A EPS
Additional Links:
Knight Therapeutics (CVE:GUD) Chart for Saturday, July, 23, 2016